Literature DB >> 11439290

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.

A Flint1, A Raben, A K Ersbøll, J J Holst, A Astrup.   

Abstract

OBJECTIVE: Peripheral infusions of glucagon-like peptide-1 (GLP-1) in humans have been shown to inhibit gastrointestinal motility and decrease hunger and energy intake. However, these investigations used supraphysiological doses. The objective of this study was to investigate the effects of a GLP-1 infusion in a physiological dose on appetite sensations, energy intake, gastric emptying, energy and substrate metabolism.
METHODS: Eighteen obese men participated in the placebo-controlled, randomized, single-blinded, cross-over study with infusion of GLP-1 or saline. Resting metabolic rate (RMR) and substrate oxidations were measured by ventilated hood before and after an energy-fixed breakfast. Gastric emptying was measured using paracetamol as a marker. Visual analogue scales were used to assess appetite sensations, thirst and comfort throughout the experiment and palatability of the test meals. Blood was sampled for analysis of hormones (GLP-1, GLP-2, glucose-dependent insulinotropic polypeptide (GIP), insulin, glucagon), and substrates (glucose, lactate, non-esterified fatty acids (NEFA), triacylglycerol (TAG)). Ad libitum energy intake at lunch was registered.
RESULTS: Following the breakfast, GLP-1 infusion suppressed ratings of hunger and prospective food consumption (P<0.05), whereas all other subjective ratings and ad libitum energy intake were unaffected. RMR, carbohydrate oxidation and gastric emptying rate were lower during the GLP-1 infusion compared with the saline infusion (P<0.001, P<0.05, P<0.0001, respectively). All plasma hormone and substrate profiles, except NEFA, were significantly reduced by GLP-1 (P<0.0001).
CONCLUSION: It is concluded that GLP-1 in physiological concentrations powerfully reduces the rate of entry of nutrients into the circulation by a reduction of gastric emptying rate in obese subjects. The effect of GLP-1 on appetite and food intake may be beneficial in weight reduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439290     DOI: 10.1038/sj.ijo.0801627

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  93 in total

Review 1.  Intestinal GLP-1 and satiation: from man to rodents and back.

Authors:  R E Steinert; C Beglinger; W Langhans
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

Review 2.  Anorexia of aging and gut hormones.

Authors:  Deniz Atalayer; Nerys M Astbury
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

3.  Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.

Authors:  Steven B Waters; Brian G Topp; Scott Q Siler; Charles M Alexander
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 5.  Gut feelings about diabetes.

Authors:  Blandine Laferrère
Journal:  Endocrinol Nutr       Date:  2012-03-03

6.  Effects of Diet on Bile Acid Metabolism and Insulin Resistance in Type 2 Diabetic Rats after Roux-en-Y Gastric Bypass.

Authors:  Cheng-Xiang Shan; Nian-Cun Qiu; Miao-E Liu; Si-Luo Zha; Xin Song; Zhi-Peng Du; Wen-Sheng Rao; Dao-Zhen Jiang; Wei Zhang; Ming Qiu
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

Review 7.  Surgical weight loss: impact on energy expenditure.

Authors:  David Thivel; Katrina Brakonieki; Pascale Duche; Béatrice Morio; Morio Béatrice; Yves Boirie; Boirie Yves; Blandine Laferrère
Journal:  Obes Surg       Date:  2013-02       Impact factor: 4.129

8.  Increasing doses of fiber do not influence short-term satiety or food intake and are inconsistently linked to gut hormone levels.

Authors:  Holly J Willis; William Thomas; Alison L Eldridge; Laura Harkness; Hilary Green; Joanne L Slavin
Journal:  Food Nutr Res       Date:  2010-06-29       Impact factor: 3.894

9.  Weight considerations in pharmacotherapy for type 2 diabetes.

Authors:  Vicky Cheng; Sangeeta R Kashyap
Journal:  J Obes       Date:  2010-09-19

10.  GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.

Authors:  Lina M Lauffer; Roman Iakoubov; Patricia L Brubaker
Journal:  Diabetes       Date:  2009-02-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.